Breaking News Instant updates and real-time market news.

MOR

MorphoSys

$23.55

-0.165 (-0.70%)

17:13
03/19/19
03/19
17:13
03/19/19
17:13

MorphoSys, I-Mab Biopharma initiate phase 2 study of TJ202 for multiple myeloma

China-based I-Mab Biopharma and MorphoSys (MOR) announced that the first patient dosing has been achieved in a phase 2 multi-center clinical study in Taiwan to evaluate an investigational human CD38 antibody TJ202/MOR202 in patients with relapsed or refractory multiple myeloma. TJ202/MOR202 is an antibody developed by MorphoSys AG. I-Mab owns the exclusive rights for development and commercialization of TJ202/MOR202 in mainland China, Hong Kong, Macao and Taiwan. TJ202/MOR202 is an investigational human monoclonal antibody derived from MorphoSys's HuCAL antibody technology. The antibody is directed against CD38 on the surface of multiple myeloma cells, which has been characterized as one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells.

  • 24

    Apr

  • 25

    Apr

  • 08

    May

MOR MorphoSys
$23.55

-0.165 (-0.70%)

12/10/18
DBAB
12/10/18
UPGRADE
DBAB
Buy
MorphoSys upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Gunnar Romer upgraded MorphoSys (MOR) to Buy and raised his price target for the shares to EUR 130 from EUR 120. The company's 115 antibody drug candidates offer "best-in-class risk diversification and value-creation potential," Romer tells investors in a research note. Further, he believes Tremfya, which is partnered with Johnson & Johnson (J&J), is on its way to becoming a multi-billion blockbuster.
01/28/19
PIPR
01/28/19
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys weakness on patent ruling a buying opportunity, says Piper Jaffray
MorphoSys (MOR) shares are indicating down 5% this morning after the U.S. District Court sided against the company and ruled three of its patents invalid in a summary judgement of its lawsuit against Johnson & Johnson's (JNJ) Janssen this weekend, Piper Jaffray analyst Danielle Brill tells investors in a research note. The analyst is not surprised by the outcome and had low expectations for MorphoSys winning the case. The invalidated patents do not impact MorphoSys' drug MOR-202, and "very little has been lost" for the company, Brill writes. As such, she recommends buying the stock on today's weakness. The analyst keeps an Overweight rating on MorphoSys with a $38 price target.
02/19/19
PIPR
02/19/19
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys should be bought on CEO retirement weakness, says Piper Jaffray
After catching up with the company, Piper Jaffray analyst Danielle Brill says all of MorphoSys' operations are reportedly unaffected and FDA discussions for MOR208 remain on track. As such, the analyst does not see "anything negative to read into" with the news of CEO Simon Maroney's plans to retire. Brill still anticipates a MOR208 Biologics License Application filing via accelerated pathway by the second half of 2019 with approval in the first half of 2020. The analyst recommends buying shares of MorphoSys on today's weakness and keeps an Overweight rating on the name with a $38 price target. The stock in midday trading is down 59c to $26.86.
02/27/19
PIPR
02/27/19
NO CHANGE
Target $38
PIPR
Overweight
Piper Jaffray more confident on MorphoSys receiving approval for MOR-208
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $38 price target on MorphoSys after hosting meetings with its management. The analyst says the discussions added to her confidence that the company's MOR-208 will be approved in the U.S. for the treatment of refractory diffuse large b-cell lymphoma by mid-2020. Brill also maintains her view that MorphoSys is "substantially undervalued" given the "sizable commercial opportunity and the proximity to potential launch".

TODAY'S FREE FLY STORIES

HIBB

Hibbett Sports

$20.53

0.13 (0.64%)

, TSCO

Tractor Supply

$105.09

1 (0.96%)

09:37
04/26/19
04/26
09:37
04/26/19
09:37
Hot Stocks
Hibbett Sports names Christine Skold as Interim CFO, effective April 26 »

Hibbett Sports (HIBB)…

HIBB

Hibbett Sports

$20.53

0.13 (0.64%)

TSCO

Tractor Supply

$105.09

1 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

  • 23

    May

  • 25

    Jul

  • 13

    Nov

SBUX

Starbucks

$77.07

0.65 (0.85%)

09:37
04/26/19
04/26
09:37
04/26/19
09:37
Hot Stocks
Starbucks CEO says competitor discounts in China not sustainable »

Kevin Johnson is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$161.03

-0.47 (-0.29%)

09:36
04/26/19
04/26
09:36
04/26/19
09:36
Recommendations
Visa analyst commentary at BMO Capital »

Visa price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

  • 29

    May

  • 05

    Jun

WNS

WNS Holdings

$56.71

0.26 (0.46%)

09:36
04/26/19
04/26
09:36
04/26/19
09:36
Recommendations
WNS Holdings analyst commentary  »

WNS Holdings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ANTM

Anthem

$256.01

5 (1.99%)

, CVS

CVS Health

$53.24

0.31 (0.59%)

09:34
04/26/19
04/26
09:34
04/26/19
09:34
Recommendations
Anthem, CVS Health analyst commentary at Cleveland Research »

Anthem won Blue Cross of…

ANTM

Anthem

$256.01

5 (1.99%)

CVS

CVS Health

$53.24

0.31 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 07

    May

  • 15

    May

  • 16

    May

  • 19

    May

  • 29

    May

  • 18

    Jun

RL

Ralph Lauren

$129.74

-2.31 (-1.75%)

09:34
04/26/19
04/26
09:34
04/26/19
09:34
Upgrade
Ralph Lauren rating change  »

Ralph Lauren upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SFLY

Shutterfly

$42.30

-0.65 (-1.51%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Upgrade
Shutterfly rating change  »

Shutterfly upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

HTBK

Heritage Commerce

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Downgrade
Heritage Commerce rating change  »

Heritage Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

SIVB

SVB Financial

$247.10

-1.84 (-0.74%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Downgrade
SVB Financial rating change  »

SVB Financial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

  • 09

    May

MAS

Masco

$37.50

-2.48 (-6.20%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Upgrade
Masco rating change  »

Masco upgraded two levels…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

FLGT

Fulgent Genetics

$7.23

-0.02 (-0.28%)

09:31
04/26/19
04/26
09:31
04/26/19
09:31
Downgrade
Fulgent Genetics rating change at Credit Suisse »

Fulgent Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

09:30
04/26/19
04/26
09:30
04/26/19
09:30
Recommendations
Pros Holdings analyst commentary  »

ProsHoldings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

CLS

Celestica

$7.29

-1.315 (-15.28%)

09:28
04/26/19
04/26
09:28
04/26/19
09:28
Downgrade
Celestica rating change at Canaccord »

Celestica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$451.24

-6.61 (-1.44%)

09:27
04/26/19
04/26
09:27
04/26/19
09:27
Conference/Events
Sherwin-Williams management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

CARO

Carolina Financial

$36.08

-0.83 (-2.25%)

09:26
04/26/19
04/26
09:26
04/26/19
09:26
Downgrade
Carolina Financial rating change  »

Carolina Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGO

Argo Group

$74.21

-0.245 (-0.33%)

09:26
04/26/19
04/26
09:26
04/26/19
09:26
Upgrade
Argo Group rating change at William Blair »

Argo shares could double…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 11

    Jun

POWI

Power Integrations

$78.11

-1.93 (-2.41%)

09:25
04/26/19
04/26
09:25
04/26/19
09:25
Recommendations
Power Integrations analyst commentary at Loop Capital »

Power Integrations price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 22

    May

HPE

HP Enterprise

$16.00

-0.27 (-1.66%)

09:25
04/26/19
04/26
09:25
04/26/19
09:25
Conference/Events
HP Enterprise management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 09

    Jul

09:25
04/26/19
04/26
09:25
04/26/19
09:25
General news
Today's U.S. GDP report »

Today's U.S. GDP…

HFWA

Heritage Financial

$30.77

-0.6 (-1.91%)

09:23
04/26/19
04/26
09:23
04/26/19
09:23
Downgrade
Heritage Financial rating change at Sandler ONeill »

Heritage Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

TAL

TAL Education

$36.22

1.81 (5.26%)

09:22
04/26/19
04/26
09:22
04/26/19
09:22
Upgrade
TAL Education rating change  »

TAL Education upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:20
04/26/19
04/26
09:20
04/26/19
09:20
General news
Fed funds futures are in rally mode »

Fed funds futures are in…

INTC

Intel

$57.59

-1.13 (-1.92%)

, AMD

AMD

$27.66

-0.8 (-2.81%)

09:19
04/26/19
04/26
09:19
04/26/19
09:19
Recommendations
Intel, AMD, Nvidia, Seagate, Western Digital, Micron analyst commentary  »

Intel report positive for…

INTC

Intel

$57.59

-1.13 (-1.92%)

AMD

AMD

$27.66

-0.8 (-2.81%)

NVDA

Nvidia

$186.84

-4.35 (-2.28%)

STX

Seagate

$46.09

-0.9 (-1.92%)

WDC

Western Digital

$52.95

-1.03 (-1.91%)

MU

Micron

$42.76

-0.27 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 30

    Apr

  • 30

    Apr

  • 08

    May

  • 15

    May

  • 16

    May

  • 22

    May

  • 03

    Jun

  • 06

    Jun

  • 10

    Jun

  • 25

    Jul

SK

Slack Technologies

$0.00

(0.00%)

09:19
04/26/19
04/26
09:19
04/26/19
09:19
Syndicate
Slack Technologies files direct listing on NYSE under symbol 'SK' »

Slack Technologies filed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
04/26/19
04/26
09:18
04/26/19
09:18
Options
Overnight activity included 391 trades in SPX and 6 trades in VIX »

391 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.